Lung Cancer Screening in Family Members and Peers of Lung Cancer Patients: a Prospective Cohort Study

Lung Cancer Clinical Trial

Official title:

Lung Cancer Screening in Family Members and Peers of Lung Cancer Patients: a Prospective Cohort Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05645731
• Other study ID #: MP-37-2023-9041
• Status: Recruiting
• Start date: May 12, 2023
• Est. completion date: April 2025

Study information

• Verified date: March 2024
• Source: McGill University Health Centre/Research Institute of the McGill University Health Centre
• Contact: Nicole Ezer, MD
• Phone: (514)-934-1934
• Email: nicole.ezer[@]mcgill.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lung cancer screening of active or former heavy smokers with yearly low-dose CT allows for earlier diagnosis and better lung cancer survival. Risk of developing lung cancer is higher among family members and close contacts of lung cancer patients, because of shared genetics, environment and life habits like smoking. The investigators want to engage lung cancer patients to refer their family members and close contacts for lung cancer screening, and evaluate if this referred population have higher risk of lung cancer than the population referred by their family doctors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: April 2025
• Est. primary completion date: April 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Lung cancer patients:

Inclusion Criteria:

• > 18 years old

• Current or former lung cancer patient

Exclusion Criteria: none

Referred participants Inclusion criteria: >18 years old Exclusion criteria: Personal history of lung cancer.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Cancer Screening
• Lung Neoplasms
• Patient Empowerment

Locations

Country	Name	City	State
Canada	MUHC	Montréal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Nicole Ezer, MD, FRCPC, MPH

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean number of referrals for lung cancer screening per participants	Mean number of referrals for lung cancer screening per participants: lung cancer participants will refer contacts directly on the REDCap questionnaire at enrollment. They will be contacted a second time 2 weeks after enrollment and asked if they referred additional people in their entourage for lung cancer screening.	2 weeks post inclusion
Primary	Mean PLCOm2012 risk prediction model score among referred participants	Mean risk of developing lung cancer in the next 6 years using the validated PLCOm2012 risk prediction model in smokers or ex-smokers referred participants that are 55 to 74 years old.	baseline
Secondary	Number of visitors on our website for referred participants	Quantification of people who visited the website for close contacts of lung cancer patients: Number of unique access to website based on google analytics data.	6 months
Secondary	Number of people who started to fill the enrollment form for referred participants.	Number of people who started to fill the enrollment form for referred participants.	6 months
Secondary	Number of referred participants who enrolled in the study.	Number of referred participants who enrolled in the study.	6 months
Secondary	PLCO score as a binary outcome (above or below 2%) among referred participants		baseline
Secondary	Proportion of LCS eligible participants who will complete lung cancer screening within 18 months of referral by a lung cancer patient	Proportion of LCS eligible participants who will complete lung cancer screening within 18 months of referral by a lung cancer patient	18 months
Secondary	Proportion of individuals who would theoretically demonstrate interest in genetic testing to assess for lung cancer risk.	Proportion of individuals who would theoretically demonstrate interest in genetic testing to assess for lung cancer risk.	baseline
Secondary	Proportion of individuals who demonstrate interest in referral to a smoking cessation program among referred participants that are current smokers	Proportion of individuals who demonstrate interest in referral to a smoking cessation program among referred participants that are current smokers	baseline
Secondary	Anxiety regarding lung cancer for referred participants	GAD7	baseline
Secondary	Anxiety regarding lung cancer for referred participants	GAD7	1 month